Doximity (DOCS) Stock Forecast & Price Target

Compare

847 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DOCS Analyst Ratings

Moderate Buy

7 Buy

8 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Doximity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DOCS Stock 12 Month Forecast

Average Price Target

$62.71

▲(6.56%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $62.71 with a high forecast of $80.00 and a low forecast of $50.00. The average price target represents a 6.56% change from the last price of $58.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","81":"$81","39.75":"$39.8","53.5":"$53.5","67.25":"$67.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$62.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,39.75,53.5,67.25,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.38,60.043076923076924,61.706153846153846,63.36923076923077,65.0323076923077,66.69538461538461,68.35846153846154,70.02153846153846,71.68461538461538,73.34769230769231,75.01076923076923,76.67384615384616,78.33692307692309,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.38,58.713076923076926,59.04615384615385,59.37923076923077,59.7123076923077,60.04538461538462,60.37846153846154,60.71153846153846,61.04461538461538,61.37769230769231,61.71076923076923,62.043846153846154,62.37692307692308,{"y":62.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.38,57.73538461538462,57.09076923076923,56.44615384615385,55.80153846153846,55.15692307692308,54.512307692307694,53.86769230769231,53.223076923076924,52.57846153846154,51.933846153846154,51.28923076923077,50.644615384615385,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.47,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.38,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$62.71

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$64

Buy

8.75%

Upside

Reiterated

06/06/25

Doximity's strong financial performance is the most significant factor in its overall score, supported by robust revenue growth and profitability. The earnings call also adds positively due to strong operational highlights. However, the high P/E ratio and mixed technical indicators moderate the overall score, indicating both potential and risks.

Allen LutzBank of America Securities

Bank of America Securities

$62

Hold

5.35%

Upside

Reiterated

07/28/25

Doximity's Mixed Market Signals: Positive Growth Amidst Budget Concerns and Rising CompetitionWe conducted our thirteenth quarterly survey on pharma advertising spend (see our prior April Survey). The survey is incrementally positive for Doximity. Top 20 pharma expects to grow spend on Doximity’s platform by the most in more than two years and mid-year upsells were better than last year. These two datapoints combined with our positive management meeting last month (link to our takeaway note here) leave us optimistic on FY1Q results. Digital marketing budgets also inflected, indicating tariff/drug pricing concerns are not impacting digital spend. Some other datapoints were surprisingly weak.

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

07/25/25

Doximity (DOCS) Gets a Buy from William BlairWe discuss each of these points in more detail in the full note.

Stan BerenshteynWells Fargo

Wells Fargo

$55

Hold

-6.54%

Downside

Reiterated

07/23/25

Doximity's Hold Rating: Balancing Positive Momentum with Legislative Risks and Market Dynamics

Jailendra SinghTruist Financial

Truist Financial

$52→$61

Hold

3.65%

Upside

Reiterated

07/17/25

Doximity price target raised to $61 from $52 at TruistDoximity price target raised to $61 from $52 at Truist

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$50→$70

Buy

18.95%

Upside

Upgraded

07/09/25

Doximity upgraded to Outperform from In Line at Evercore ISIDoximity upgraded to Outperform from In Line at Evercore ISI

Michael ChernyLeerink Partners

Leerink Partners

$73

Buy

24.04%

Upside

Reiterated

06/17/25

Potential Regulatory Changes in Pharmaceutical Advertising Boost Doximity's Prospects

David LarsenBTIG

BTIG

$80

Buy

35.94%

Upside

Upgraded

06/02/25

Doximity upgraded to Buy from Neutral at BTIGDoximity upgraded to Buy from Neutral at BTIG

Anne SamuelJ.P. Morgan

J.P. Morgan

$63→$60

Hold

1.95%

Upside

Reiterated

05/27/25

J.P. Morgan Sticks to Its Hold Rating for Doximity (DOCS)

David RomanGoldman Sachs

Goldman Sachs

$80→$50

Hold

-15.04%

Downside

Reiterated

05/21/25

Doximity price target lowered to $50 from $80 at Goldman SachsDoximity price target lowered to $50 from $80 at Goldman Sachs

Vikram KesavabhotlaRobert W. Baird

Robert W. Baird

$87→$65

Buy

10.45%

Upside

Reiterated

05/20/25

Doximity price target lowered to $65 from $87 at BairdDoximity price target lowered to $65 from $87 at Baird

Brian PetersonRaymond James

Raymond James

$83→$65

Buy

10.45%

Upside

Reiterated

05/16/25

Doximity Inc (DOCS) PT Lowered to $65 at Raymond JamesRaymond James analyst Brian Peterson lowered the price target on Doximity Inc (NYSE: DOCS) to $65.00 (from $83.00) while maintaining a Outperform rating.

Craig HettenbachMorgan Stanley

Morgan Stanley

$60

Hold

1.95%

Upside

Reiterated

05/16/25

Doximity: Strong Performance Amidst Cautious Outlook Warrants Hold Rating

Steven ValiquetteMizuho Securities

Mizuho Securities

$65→$60

Hold

1.95%

Upside

Reiterated

05/16/25

Doximity price target lowered to $60 from $65 at MizuhoDoximity price target lowered to $60 from $65 at Mizuho

Scott BergNeedham

Needham

$67

Buy

13.85%

Upside

Reiterated

05/16/25

Doximity's Strong Performance and Strategic Positioning Justify Buy Rating Despite Conservative Revenue Guidance

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$64

Buy

8.75%

Upside

Reiterated

06/06/25

Allen LutzBank of America Securities

Bank of America Securities

$62

Hold

5.35%

Upside

Reiterated

07/28/25

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

07/25/25

Doximity (DOCS) Gets a Buy from William BlairWe discuss each of these points in more detail in the full note.

Stan BerenshteynWells Fargo

Wells Fargo

$55

Hold

-6.54%

Downside

Reiterated

07/23/25

Doximity's Hold Rating: Balancing Positive Momentum with Legislative Risks and Market Dynamics

Jailendra SinghTruist Financial

Truist Financial

$52→$61

Hold

3.65%

Upside

Reiterated

07/17/25

Doximity price target raised to $61 from $52 at TruistDoximity price target raised to $61 from $52 at Truist

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$50→$70

Buy

18.95%

Upside

Upgraded

07/09/25

Doximity upgraded to Outperform from In Line at Evercore ISIDoximity upgraded to Outperform from In Line at Evercore ISI

Michael ChernyLeerink Partners

Leerink Partners

$73

Buy

24.04%

Upside

Reiterated

06/17/25

Potential Regulatory Changes in Pharmaceutical Advertising Boost Doximity's Prospects

David LarsenBTIG

BTIG

$80

Buy

35.94%

Upside

Upgraded

06/02/25

Doximity upgraded to Buy from Neutral at BTIGDoximity upgraded to Buy from Neutral at BTIG

Anne SamuelJ.P. Morgan

J.P. Morgan

$63→$60

Hold

1.95%

Upside

Reiterated

05/27/25

J.P. Morgan Sticks to Its Hold Rating for Doximity (DOCS)

David RomanGoldman Sachs

Goldman Sachs

$80→$50

Hold

-15.04%

Downside

Reiterated

05/21/25

Doximity price target lowered to $50 from $80 at Goldman SachsDoximity price target lowered to $50 from $80 at Goldman Sachs

Vikram KesavabhotlaRobert W. Baird

Robert W. Baird

$87→$65

Buy

10.45%

Upside

Reiterated

05/20/25

Doximity price target lowered to $65 from $87 at BairdDoximity price target lowered to $65 from $87 at Baird

Brian PetersonRaymond James

Raymond James

$83→$65

Buy

10.45%

Upside

Reiterated

05/16/25

Craig HettenbachMorgan Stanley

Morgan Stanley

$60

Hold

1.95%

Upside

Reiterated

05/16/25

Doximity: Strong Performance Amidst Cautious Outlook Warrants Hold Rating

Steven ValiquetteMizuho Securities

Mizuho Securities

$65→$60

Hold

1.95%

Upside

Reiterated

05/16/25

Doximity price target lowered to $60 from $65 at MizuhoDoximity price target lowered to $60 from $65 at Mizuho

Scott BergNeedham

Needham

$67

Buy

13.85%

Upside

Reiterated

05/16/25

Doximity's Strong Performance and Strategic Positioning Justify Buy Rating Despite Conservative Revenue Guidance

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Doximity

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+6.42%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +6.42% per trade.

3 Months

xxx

Success Rate

5/9 ratings generated profit

Average Return

-3.10%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of -3.10% per trade.

1 Year

Vikram KesavabhotlaRobert W. Baird

Success Rate

6/17 ratings generated profit

Average Return

+15.86%

reiterated a buy rating 2 months ago

Copying Vikram Kesavabhotla's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +15.86% per trade.

2 Years

xxx

Success Rate

10/17 ratings generated profit

Average Return

+36.11%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +36.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DOCS Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DOCS has received 15 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. DOCS average Analyst price target in the past 3 months is 62.71.

Each month's total comprises the sum of three months' worth of ratings.

DOCS Financial Forecast

DOCS Earnings Forecast

Next quarter’s earnings estimate for DOCS is $0.30 with a range of $0.27 to $0.33. The previous quarter’s EPS was $0.38. DOCS beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.06% of the time in the same period. In the last calendar year DOCS has Outperformed its overall industry.

DOCS Sales Forecast

Next quarter’s sales forecast for DOCS is $139.43M with a range of $137.72M to $140.06M. The previous quarter’s sales results were $138.29M. DOCS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.30% of the time in the same period. In the last calendar year DOCS has Outperformed its overall industry.

DOCS Stock Forecast FAQ

What is DOCS’s average 12-month price target, according to analysts?

Based on analyst ratings, Doximity’s 12-month average price target is 62.71.

What is DOCS’s upside potential, based on the analysts’ average price target?

Doximity has 6.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DOCS a Buy, Sell or Hold?

Doximity has a consensus rating of Moderate Buy which is based on 7 buy ratings, 8 hold ratings and 0 sell ratings.

What is Doximity’s price target?

The average price target for Doximity is 62.71. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $50.00. The average price target represents 6.56% Increase from the current price of $58.85.

What do analysts say about Doximity?

Doximity’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of DOCS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Doximity (DOCS) Stock Forecast & Price Target

DOCS Analyst Ratings

DOCS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Doximity

DOCS Analyst Recommendation Trends

DOCS Financial Forecast

DOCS Earnings Forecast

DOCS Sales Forecast

DOCS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts